ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of December 16, 2024, ANVS stock price declined to $5.15 with 26,720 million shares trading.

ANVS has a beta of 4.45, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.09 to the broad based SPY ETF.

ANVS has a market cap of $71.06 million. This is considered a Micro Cap stock.

In the last 3 years, ANVS traded as high as $23.91 and as low as $4.53.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC.

ANVS has underperformed the market in the last year with a price return of -49.0% while the SPY ETF gained +30.3%. ANVS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.7% and -23.2%, respectively, while the SPY returned +8.1% and +0.5%, respectively.

ANVS support price is $5.00 and resistance is $5.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.